Status:
UNKNOWN
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501
Lead Sponsor:
REGENXBIO Inc.
Conditions:
Homozygous Familial Hypercholesterolemia (HoFH)
Eligibility:
All Genders
18+ years
Brief Summary
This long-term observational study is designed to follow subjects who, during another Clinical Study, received gene therapy treatment used to treat their Homozygous Familial Hypercholesterolemia (HoFH...
Detailed Description
Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic metabolic disorder characterized by absent or severely reduced capacity to catabolize circulating LDL particles by the hepatic LDL rec...
Eligibility Criteria
Inclusion
- To be eligible to participate in this study, a participant must have previously received RGX-501 in a separate parent trial, and the participant or participant's legal guardian(s) is/(are) willing and able to provide written, signed informed consent after the nature of the study has been explained, prior to any research-related procedures.
Exclusion
- None
Key Trial Info
Start Date :
September 30 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 29 2025
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04080050
Start Date
September 30 2019
End Date
September 29 2025
Last Update
March 9 2023
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbus Location
Columbus, Ohio, United States, 43210
2
Portland location
Portland, Oregon, United States, 97239
3
Philadelphia location
Philadelphia, Pennsylvania, United States, 19104
4
Nashville location
Nashville, Tennessee, United States, 37232